DNL343 for Amyotrophic Lateral Sclerosis
Trial Summary
What is the purpose of this trial?
This trial tests a new drug called DNL343 in people with ALS. It aims to see if the drug is safe and how it affects the disease. Researchers will study how the drug moves through the body and its impact on ALS symptoms.
Research Team
Linus Sun, MD, PhD
Principal Investigator
Denali Therapeutics Inc.
Eligibility Criteria
Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either DNL343 or placebo for 28 days to evaluate safety, pharmacokinetics, and pharmacodynamics
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension
Participants may opt into continuation of treatment with DNL343 for 18 months
Treatment Details
Interventions
- DNL343
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Denali Therapeutics Inc.
Lead Sponsor